A*STAR Singapore Immunology Network (A*STAR SIgN)

A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.

Two coronavirus experts suggest that the best way to control an outbreak may be to first understand viral biology and behavior in animals and humans.

Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder clinical outcomes, with implications for COVID-19 treatments and vaccines.

An international genetics consortium seeks to unravel the mystery of why COVID-19 infection is silent in some cases and lethal in others.

Understanding how closely related coronaviruses circulate seasonally could impact the timing of vaccination against SARS-CoV-2.

Two linear peptides identified by A*STAR researchers on the SARS-CoV-2 spike protein may improve the specificity of serological assays and show potential as vaccine candidates.

Curiox Biosystems, an A*STAR spin-off company, specializes in automated and quantitative cell analysis. Its CEO, Namyong Kim, shares the story of the company’s success.

The developmental origins of human macrophages suggest that scientists may need to rethink the way they study these important immune cells.

A*STAR scientists have uncovered a novel surface marker that identifies stem cells and potential cancer stem cells in the distal stomach.

Single-cell genomic technology is providing fresh perspectives on the origins of microglia, ancient immune sentinels found in the brain.

Researchers at A*STAR have uncovered a new role for a subset of immune cells in HIV infection and transmission.

Scientists are one step closer to developing effective treatments against Plasmodium vivax parasites, thanks to the ability to culture one of its closest cousins.